IN.PACT Admiral drug-coated balloon — the only DCB with reported 5-year data from a real-world global study.1
This matters now more than ever.||
IN.PACT Admiral DCB provides 180 days of sustained drug release in the tissue.5
Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT Admiral DCB helped get him back on his feet.
More information (see more) Less information (see less)
Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Based on sales units sold since CE Mark. Units sold divided by units per procedure.
Primary patency not assessed after 3 years.
Data and additional comparative data on file with Medtronic.
The potential for fewer visits to a healthcare provider may reduce the exposure to COVID-19-related risks.
Presented by Thomas Zeller, M.D., at VIVA 2020.
Schneider PA, Laird J, Tepe G, et al. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. January 2018;11(1):e005891.
Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. June 2019;12(6):e007702.
Based on the mortality data from the LEVANT 2 IDE in the Lutonix™* DCB IFU (BAW1387400r6) and the IN.PACT SFA Trial in the IN.PACT™ Admiral™ DCB IFU (M052624T001).
Virmani, R. Charing Cross, 2016: Arterial wall response to drug coated balloon, data on file.
Gongora CA, Shibuya M, Wessler JD, et al. Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. JACC Cardiovasc Interv. July 2015;8(8):1115-1123.
Spectranetics Stellarex 035 DCB Advisory Panel Briefing Package. June 2019.